US · Healthcare · Biotechnology
EPS came in at -0.38 against a street estimate of -0.43 — a beat of 11.6%.
Analysts rate Solid Biosciences LLC a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $18.62.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 11.23% |
| Perceptive Advisors LLC | 11.10% |
| Bain Capital Life Sciences Investors, LLC | 9.15% |
| Siren, L.L.C. | 7.17% |
| BlackRock Inc | 6.47% |
| FMR Inc | 6.41% |
| Armistice Capital, LLC | 3.99% |
| State Street Corp | 3.89% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SOLID BIOSCIENCES INC. - 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash & Securities Position (June 30, 2026): $377.7 million in cash, ca | 2026-08-06 |
| Company announcement · Q3 2026 SOLID BIOSCIENCES INC. - 8-K SUMMARY HEADLINE NUMBERS • Company filed prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million | 2026-08-06 |
| Shareholder vote results · Q2 2026 SOLID BIOSCIENCES INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 10, 2026 • Company trades on Nasdaq Global Select M | 2026-06-10 |
| Quarterly report · Q1 2026 SOLID BIOSCIENCES INC. — 10-Q SUMMARY FOR RETAIL INVESTORS Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Cash position: $297.1 mill | 2026-05-12 |
| Proxy statement · Q2 2026 SOLID BIOSCIENCES INC. – 2026 ANNUAL MEETING PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class II Directors—Clare K | 2026-04-23 |
| Board / officer change · Q2 2026 SOLID BIOSCIENCES INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Solid Biosciences Inc. (Nasdaq: SLDB) • Filing Date: April 10, 2026 • Headquarters: | 2026-04-10 |
| Annual report FY2025 SOLID BIOSCIENCES INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Solid Biosciences Inc., ticker SLDB, listed on Nasdaq Global | 2026-03-19 |
| Reg FD disclosure · Q1 2026 SOLID BIOSCIENCES INC. – 8-K SUMMARY (MARCH 11, 2026) HEADLINE NUMBERS • 40 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial as of March 11, 2 | 2026-03-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Solid Biosciences LLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.